"
Team:SupBiotech-Paris/Acknowledgement
From 2009.igem.org
(Difference between revisions)
Enguerrand (Talk | contribs) |
Enguerrand (Talk | contribs) |
||
| Line 4: | Line 4: | ||
{| | {| | ||
|We want to acknowledge : | |We want to acknowledge : | ||
| + | | | ||
|- | |- | ||
| - | |||
|} | |} | ||
{| | {| | ||
| - | == | + | ==UMR CNRS 8121 from the Gustave Roussy Institute== |
| - | + | ||
| - | + | ||
*Lluis M. Mir | *Lluis M. Mir | ||
| Line 17: | Line 15: | ||
==INSERM U872== | ==INSERM U872== | ||
| - | |||
| - | |||
*Srinivas Kaveri | *Srinivas Kaveri | ||
| Line 25: | Line 21: | ||
==AnyGenes== | ==AnyGenes== | ||
| - | |||
*Benyoussef Naimi | *Benyoussef Naimi | ||
Revision as of 17:04, 19 August 2009
Project
Introduction Current therapies Gene therapies DVS Concept Tissue Vector Cell Vector Therapeutic plasmid Conclusion Implementation Tissue targeting Antitumor action Treatment modeling Conclusion
Ressources
BioBricks Material & Method Bibliography
Ethics & Safety
| We want to acknowledge : |
Contents |
UMR CNRS 8121 from the Gustave Roussy Institute
- Lluis M. Mir
- Karim Benihoud
INSERM U872
- Srinivas Kaveri
AnyGenes
- Benyoussef Naimi
Our Sponsors
- Embassy of France in Washington [http://fr.ambafrance-us.org/spip.php?rubrique=[Link]]
- Eurogentec [http://www.eurogentec.com/eu-home.html [Link]]
- Takara [http://www.takarabioeurope.com/ [Link]]
- Clonetec [http://www.clontech.com/ [Link]]
- Promega [http://www.promega.com/ [Link]]
- Sigma-Aldrich [http://www.sigmaaldrich.com/ [Link]]
- Qiagen [http://www1.qiagen.com/ [Link]]
